BioButton (patient monitoring device)

2022: Medtronic starts selling the device

On September 2, 2022, it became known that Medtronic had expanded its portfolio of patient monitoring devices with a partnership with BioIntelliSense. Medtronic will have exclusive distribution rights to BioButton's continuous monitoring wearable device, which BioIntelliSense developed.

BioButton will sell under the Medtronic brand. The collaboration will be particularly beneficial for hospitals amid a growing shortage of health care workers and rising health care costs, said BioIntelliSense CEO James Mault, MD.

Medtronic starts selling wearable devices that detect symptoms of infectious diseases

This advanced remote physiological monitoring simplifies the delivery of care by promoting personalized patient care, clinical workflow automation, and proactive clinical intervention, Mault said.

The financial terms of the deal were not disclosed.

The BioButton is a small device about 2 cm in diameter that attaches to the patient's chest for 90 days or more. It works around the clock to collect vital condition indicators, collecting up to 1,440 readings each day. The device will be used both in hospital settings and within the first 30 days after transferring patients from the hospital to home treatment.

The device measures about two dozen indicators, including skin temperature, resting heart rate and breathing rate, body position, physical activity level and sleep quality. It also conducts gait analysis, tracking the symmetry of steps, their sequence and the effort applied, and can recognize symptoms such as vomiting, sneezing and coughing, which can indicate infectious diseases.

All these measurements are automatically transmitted via Bluetooth to the mobile application and to the online portal BioIntelliSense. On the portal, physicians can access reports illustrating progress in patient vital signs readings over time. The system can be programmed to send alerts if these indicators are outside the specified ranges.^[1]

Notes